A5012414361- Ocular Diseases and Behçet’s Syndrome
- Systemic Lupus Erythematosus Research
- Vasculitis and related conditions
- Sarcoidosis and Beryllium Toxicity Research
- Retinal and Optic Conditions
- Otitis Media and Relapsing Polychondritis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Spondyloarthritis Studies and Treatments
- Infectious Diseases and Tuberculosis
- Dermatological and COVID-19 studies
- Systemic Sclerosis and Related Diseases
- Inflammatory Bowel Disease
- Renal Diseases and Glomerulopathies
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Autoimmune and Inflammatory Disorders
- Ophthalmology and Eye Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Autoimmune and Inflammatory Disorders Research
- Cell Adhesion Molecules Research
- Ocular Oncology and Treatments
- Neuroendocrine Tumor Research Advances
- Rheumatoid Arthritis Research and Therapies
- Atherosclerosis and Cardiovascular Diseases
- IgG4-Related and Inflammatory Diseases
Instituto de Investigación Marqués de Valdecilla
2020-2024
Marqués de Valdecilla University Hospital
2018-2024
Center for Rheumatology
2022-2023
Universidad de Cantabria
2020-2022
Graves’ orbitopathy (GO) is the most common extrathyroidal manifestation of disease (GD). Our aim was to assess efficacy and safety Tocilizumab (TCZ) in GO refractory conventional therapy. This an open-label multicenter study glucocorticoid-resistant treated with TCZ. The main outcomes were best-corrected visual acuity (BVCA), Clinical Activity Score (CAS) intraocular pressure (IOP). These outcome variables assessed at baseline, 1st, 3rd, 6th 12th month after TCZ therapy onset. severity...
In the present study, we aimed to report our experience with rituximab (RTX) in treatment of patients ILD associated AD (AD-ILD) at a single center. For this purpose, clinical characteristics, radiological findings, and pulmonary function tests (PFTs) RTX-treated AD-ILD-patients seen from May 2016 until March 2020 referral center for individuals were retrospectively reviewed. Additionally, an updated literature review was conducted. A total 26 (mean age 58.3 ± 11.1 years diagnosis) included....
Visual involvement is the most feared complication of giant cell arteritis (GCA). Information on efficacy tocilizumab (TCZ) for this scarce and controversial.We assessed a wide series GCA treated with TCZ, to evaluate its role in prevention new visual complications when manifestation was already present before initiation TCZ.This an observational multicenter study patients TCZ.Patients were divided into two subgroups according presence or absence TCZ onset. manifestations classified...
Blau syndrome (BS) is an autoinflammatory disorder characterized by non-caseating granulomatous dermatitis, arthritis, and uveitis. We present a case of refractory severe BS that was treated with the Janus kinase inhibitors (JAKINIBS), Tofacitinib (TOFA) then Baricitinib (BARI). Our aim to describe clinical immunological outcomes after treatment JAKINIBS. Blood tests serum samples were obtained during follow-up TOFA BARI. assessed their effects on outcomes, acute phase reactants, absolute...
: Neuro-Behçet's disease (NBD) is one of the most severe complications Behçet's (BD). The incidence NBD varies widely worldwide. This study aimed to estimate its current in Northern Spain.
To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). Multicentre study CZP-treated patients with IMID refractory conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness retinal vasculitis. These variables were compared between baseline, first week, first, third, sixth months, second year. We...
<h3>Background:</h3> Inflammatory ocular pathology (IOP) includes internal (uveitis) and external [mainly surface (OSP) such as epi/scleritis peripheral ulcerative keratitis (PUK)] involvement. OSP may be a severe conditions refractory to conventional immunosuppressants even biological therapy. Janus Kinase inhibitors (JAKINIB) had shown efficacy in cases of different immune-mediated inflammatory diseases (IMID). <h3>Objectives:</h3> In patients with treated JAKINIB our aims were <b>a</b>)...
Background: Inflammatory bowel disease (IBD), which includes Crohn’s (CD), Ulcerative colitis (UC), and undetermined may be related to psoriasis psoriatic arthritis (PsA). Biologic therapy (BT) is useful in PsA IBD but paradoxically has been IBD. Objectives: In a wide series of PsA, our aim was assess ) the epidemiological clinical features associated b its relationship with BT. Methods: All unselected consecutive patients studied single reference University Hospital : (CASPAR criteria) IBD:...
<h3>Background:</h3> Behçet's disease (BD) is characterized by heterogeneity of clinical manifestations due to involvement variable blood vessels. <h3>Objectives:</h3> identify phenotypes using cluster analysis. <h3>Methods:</h3> a model-based clustering relaying on 16 variables was performed in retrospective cohort 120 BD patients, diagnosed and follow-up from January 1, 1980 December 31, 2019 3 hospital at Northern Spain (Cantabria). Chi-square test ANOVA were used compare categorical...
<h3>Background:</h3> Uveitis is a frequent extraarticular manifestation of axial Spondyloarthritis (axSpA), specifically anterior uveitis. Effects biological therapy on uveitis associated to axSpA are poorly understood. <h3>Objectives:</h3> To assess in <b>a</b>) the frequency and clinical features; <b>b</b>) its association with activity, <b>c</b>) effectiveness synthetic disease-modifying drugs and, <b>d</b>) ocular surface pathology. <h3>Methods:</h3> A retrospective longitudinal study...
<h3>Background</h3> Tocilizumab (TCZ) is the only biologic therapy approved for giant cell arteritis (GCA). Clinical trials with TCZ in GCA was performed intravenous (iv) a phase 2 trial <b>[1]</b>, and subcutaneous (sc) 3 GiACTA <b>[2].</b> There general agreement on initial/maintenance dose, but duration of not well established. In trial, after one year TCZ, most patients had relapse withdrawal. <h3>Objectives</h3> To assess predictive factors clinical practice scenario. <h3>Methods</h3>...
The leading cause of blindness due to non-infectious uveitis is cystoid macular edema (CME). Behçet's disease (BD) one the most commonly conditions related CME.
Ocular disease, such as scleritis and peripheral ulcerative keratitis (PUK), may be a serious ocular complication. We present patient with severe refractory PUK treated baricitinib. A review of the literature on Janus kinase inhibitors (JAKINIB) in surface pathology was also performed. For review, search PubMed, Embase, Cochrane library carried out from inception until 31 May 2021, including conference proceedings four major rheumatology congresses. All original research articles studying...